← Leaderboards
Igor B Roninson
University Of Illinois At Chicago
$18,517,458
Attributed
$21,675,620
Total exposure
14
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.1M · FY2005–24$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$46,409,748 · 15
By mechanism
P20$34,791,601 · 6
R01$7,749,826 · 6
R44$1,977,275 · 1
R33$1,523,921 · 1
R21$367,125 · 1
Top collaborators
- Hippokratis Kiaris4 shared
- Eugenia V Broude3 shared
- Hexin Chen3 shared
- Mengqian Chen2 shared
- Taixing Cui2 shared
- John F Eberth2 shared
- Michael B Lilly2 shared
- Yusuke Shiozawa2 shared
Most similar at University Of Illinois At Chicago
Same institution · by research overlap
- James P Lash$30,453,152
- Robert H Costa$14,892,370
- Bellur S Prabhakar$8,432,775
- Tonda L Hughes$11,135,841
- Richard J Derman$16,600,962
Others in their field
Top investigators on “Programs”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,641,009,751
- Leonard Freedman · Leidos Biomedical Research, Inc.$994,984,644
- Lawrence Corey · Fred Hutchinson Cancer Center$730,186,538
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$609,313,548
Research focus
ProgramsTargeted TreatmentCenters Of Research ExcellenceFacultyScientistFosteringFundingFlow CytometryEnvironmentSuccessCell LineResearch PersonnelApplications GrantsCareer DevelopmentMeetingsBaseMalignant NeoplasmsMentorsGenetic TranscriptionPharmaceutical PreparationsCollaborationsNeoplastic CellPilot ProjectsReporting
Grant awards (67)
Preventing adaptive drug resistance through Mediator kinase inhibition$582,679
R01 · FY2024 · CA · contact PI
Admin-Core$289,084
P20 · FY2024 · GM · contact PI
Motherhood, pair bonding and parental relatedness as modulators of epigenetic aging$289,084
P20 · FY2024 · GM
Center for Targeted Therapeutics$2,235,000
P20 · FY2023 · GM
Admin-Core$1,063,913
P20 · FY2023 · GM · contact PI
Center for Targeted Therapeutics 2$1,063,913
P20 · FY2023 · GM
Admin-Core$910,408
P20 · FY2023 · GM · contact PI
Preventing adaptive drug resistance through Mediator kinase inhibition$596,858
R01 · FY2023 · CA · contact PI
Synthetic Transcriptional Activators for Cancer Immunotherapy$199,185
P20 · FY2023 · GM
Center for Targeted Therapeutics$2,235,000
P20 · FY2022 · GM
Admin-Core$772,891
P20 · FY2022 · GM · contact PI
Preventing adaptive drug resistance through Mediator kinase inhibition$607,349
R01 · FY2022 · CA · contact PI
Administrative supplement for the flow cytometry cell sorter purchase$247,396
P20 · FY2022 · GM · contact PI
Synthetic Transcriptional Activators for Cancer Immunotherapy$218,024
P20 · FY2022 · GM
Center for Targeted Therapeutics$2,235,000
P20 · FY2021 · GM · contact PI
CDK8/19 inhibitors for therapy of advanced prostate cancer$846,340
R44 · FY2021 · CA
Admin-Core$765,350
P20 · FY2021 · GM · contact PI
Center for Targeted Therapeutics$372,500
P20 · FY2021 · GM · contact PI
METABOLIC ANALYSIS INSTRUMENTATION TO ENHANCE TARGETED THERAPEUTICS STUDIES$249,035
P20 · FY2021 · GM · contact PI
Center for Targeted Therapeutics$2,235,000
P20 · FY2020 · GM · contact PI
CDK8/19 inhibitors for therapy of advanced prostate cancer$1,130,935
R44 · FY2020 · CA
Admin-Core$765,351
P20 · FY2020 · GM · contact PI
Center for Targeted Therapeutics$2,235,000
P20 · FY2019 · GM · contact PI
Admin-Core$765,349
P20 · FY2019 · GM · contact PI
Center for Targeted Therapeutics$2,200,465
P20 · FY2018 · GM · contact PI
A & R$439,499
P20 · FY2018 · GM · contact PI
Administration Core$364,038
P20 · FY2018 · GM · contact PI
A novel approach for transforming decelluarized vessel grafts into small-diameter arteries$200,250
R21 · FY2018 · EB
Center for Targeted Therapeutics$2,200,465
P20 · FY2017 · GM · contact PI
A & R$419,997
P20 · FY2017 · GM · contact PI
Administration Core$352,088
P20 · FY2017 · GM · contact PI
A novel approach for transforming decelluarized vessel grafts into small-diameter arteries$166,875
R21 · FY2017 · EB
Center for Targeted Therapeutics$2,200,465
P20 · FY2016 · GM · contact PI
A & R$447,917
P20 · FY2016 · GM · contact PI
Administration Core$365,680
P20 · FY2016 · GM · contact PI
Center for Targeted Therapeutics$2,200,465
P20 · FY2015 · GM · contact PI
A & R$439,499
P20 · FY2015 · GM · contact PI
Administration Core$364,038
P20 · FY2015 · GM · contact PI
Center for Targeted Therapeutics$2,535,340
P20 · FY2014 · GM · contact PI
A & R$739,499
P20 · FY2014 · GM · contact PI
Administration Core$375,663
P20 · FY2014 · GM · contact PI
Secretory Patterns of Senescent Tumor Cells$277,202
R01 · FY2011 · AG · contact PI
Secretory Patterns of Senescent Tumor Cells$330,159
R01 · FY2010 · AG · contact PI
Secretory Patterns of Senescent Tumor Cells$333,494
R01 · FY2009 · AG · contact PI
Secretory Patterns of Senescent Tumor Cells$333,494
R01 · FY2008 · AG · contact PI
Secretory Patterns of Senescent Tumor Cells$340,300
R01 · FY2007 · AG · contact PI
p21 As an Inducer of Disease-Associated gene expression$346,658
R01 · FY2006 · AG · contact PI
Function-based selection of target genes in tumor cells$527,922
R33 · FY2005 · CA
p21 As an Inducer of Disease-Associated gene expression$355,000
R01 · FY2005 · AG
Mitotic Catastrophe in Tumor Cells$293,700
R01 · FY2005 · CA
Accelerated senescence in tumor cells$273,900
R01 · FY2005 · CA
Function-based selection of target genes in tumor cells$516,468
R33 · FY2004 · CA
p21 As an Inducer of Disease-Associated gene expression$330,001
R01 · FY2004 · AG
Mitotic Catastrophe in Tumor Cells$293,700
R01 · FY2004 · CA
Accelerated senescence in tumor cells$273,900
R01 · FY2004 · CA
Function-based selection of target genes in tumor cells$479,531
R33 · FY2003 · CA
p21 As an Inducer of Disease-Associated gene expression$222,860
R01 · FY2003 · AG
Mitotic Catastrophe in Tumor Cells$215,630
R01 · FY2003 · CA
Accelerated senescence in tumor cells$164,093
R01 · FY2003 · CA
Accelerated senescence in tumor cells$106,294
R01 · FY2003 · CA
p21 As an Inducer of Disease-Associated gene expression$85,410
R01 · FY2003 · AG
Mitotic Catastrophe in Tumor Cells$73,749
R01 · FY2003 · CA
p21 As an Inducer of Disease-Associated gene expression$308,270
R01 · FY2002 · AG
Mitotic Catastrophe in Tumor Cells$277,449
R01 · FY2002 · CA
Accelerated senescence in tumor cells$256,184
R01 · FY2002 · CA
Accelerated senescence in tumor cells$256,184
R01 · FY2001 · CA
TARGETING TUMOR CELLS WITH GENETIC SUPPRESSOR ELEMENTS$215,309
R01 · FY2000 · CA